BSECompany Update5d ago · 15 Aug 2026, 03:41 pm
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
AstraZeneca Pharma India Ltd · 506820
✦ AI SummaryMgmt Change
AstraZeneca Pharma India Ltd has announced an interaction with analysts/investors scheduled for August 19, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
6e403fe6-4189-47b6-bfcb-097108b97b38.pdf
View document text
August 15, 2026
The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai - 400001
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051
Dear Sirs/ Madam,
Sub: Intimation of Schedule of interaction with Analyst/ Investor
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations,
2015, we hereby inform that an interaction with analyst/ investor is scheduled to be held as per the
details given hereunder:
Day, Date Type of Interaction with Location
interaction
Wednesday, One-on-one Institutional Investor Virtual
August 19, 2026 Meeting
Dates are subject to change. Changes may happen due to exigencies on part of the Company /Analyst/
Investor.
We request you to take the same on record.
Thanking you,
For AstraZeneca Pharma India Limited
Tanya Sanish
Company Secretary & Compliance Officer